EGFR and lung cancer: A study reported that the blockade of EGFR by afatinib resulted in decreased STAT1 and IRF-1 levels, and disabled the IFN-γ-STAT1-mediated PD-L1 axis in vitro and in vivo for oral cancer and lung cancer [42].